Jazz Pharmaceuticals JAZZ Non-deductible contingent consideration payments
Non-deductible contingent consideration payments at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:EffectiveIncomeTaxRateReconciliationNonDeductibleContingentConsiderationPaymentsAmount.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's non-deductible contingent consideration payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's non-deductible contingent consideration payments?
- Jazz Pharmaceuticals (JAZZ) reported non-deductible contingent consideration payments of $1.91M in Q4 2025.
- What does non-deductible contingent consideration payments mean?
- The dollar value of acquisition-related earn-out payments that are not tax-deductible.
- How do you interpret non-deductible contingent consideration payments?
- Lower values are preferred, as they indicate that acquisition-related costs are more tax-efficient.
- How does non-deductible contingent consideration payments compare across companies?
- Specific to companies with active M&A strategies involving milestone-based earn-outs.